Competition winner aims to transform cell culture space
company has developed a novel bioproduction method to produce growth factors, cytokines and hormones necessary for efficient and scalable production.
Dr Jade Pellet, CSO and co-founder of Alt Biotech, said: “Our aim is to contribute towards innovation in the cell culture space, helping to propel game-changing solutions like cell therapies and cellular agriculture into the mainstream. Our proprietary process relies on a new, more sustainable and scalable bioproduction method, combined with a microorganism that produces protein at a higher rate than E. coli alternatives.”
“The EVOLVE manual pipettes we received from Integra have allowed us to set aside dedicated equipment for each of our development workflows, eliminating any chance of cross contamination. The multichannel units have proved to be particularly valuable, helping us to minimise repetitive tasks, increase throughput, reduce well-to-well variation and expand our experimental batch sizes.
Jade Pellet, CSO and co-founder Alt Biotech
Bringing a fresh approach to the cell culture market, Alt Biotech has been chosen as a winner of the ‘Integra supports start-ups’ competition, receiving 12 EVOLVE manual pipettes and $1000 worth of GRIPTIPS® pipette tips to help develop its potentially game-changing technologies.
Founded to address the issues of high costs and ethical considerations around the use of animal-based growth factors commonly used to promote cell development and proliferation, the
“In addition, the ECO rack GRIPTIPS are a much more sustainable solution than the temperamental alternatives we were previously using, simply snapping into place and putting an end to the constant inconvenience of poorly fitting tips. Winning the ‘Integra supports start-ups’ competition has given our workflows a much- needed efficiency boost, allowing us to streamline the development processes that will ultimately provide the cell culture industry with affordable growth factors, cytokines and hormones,“ Dr Pellet added.
More information online:
ilmt.co/PL/NAnR 62434pr@reply-direct.com
Pro-aging blood signature identified in people living with HIV
Research led by the Wistar Institute’s professor Mohamed Abdel- Mohsen, PhD and other collaborators, have identified sugar abnormalities in the blood that may promote biological aging and inflammation in people living with HIV (PLWH).
Despite advances in HIV treatment, notably the success of antiretroviral therapy (ART) in suppressing the virus to undetectable levels, HIV remains incurable, with the virus persisting in a dormant state within the body. This chronic presence is linked to long-term health issues, including persistent inflammation and a higher prevalence of aging-related diseases such as cancer and neurocognitive disorders. These conditions tend to occur more frequently and at an earlier age in PLWH compared to the general population.
While many factors in the body can contribute to accelerated biological aging, researchers focused on a novel factor: abnormalities of the human glycome — the totality of the various sugar structures circulating throughout the body. Previous studies have established a connection between aging and shifts in the glycan composition of immunoglobulins (IgGs), which are critical for immune regulation. As people age, their IgGs lose anti- inflammatory properties and gain pro-inflammatory characteristics.
Abdel-Mohsen’s research investigates whether living with a chronic viral infection, such as HIV infection, exacerbates these changes, leading to premature aging and related diseases.
By comparing glycan profiles in more than 1200 individuals,
both with and without HIV, the team discovered that PLWH exhibit elevated levels of inflammatory and pro-aging IgG glycan signatures. In a remarkable step forward, the team developed a machine-learning model that uses these glycan signatures to estimate the biological age of PLWH and assess the rate of aging acceleration. This glycan signature also has the potential to predict the onset of comorbid conditions in PLWH, such as cancer, years in advance.
“Utilising glycan signatures to predict early onset of diseases in people living with HIV marks a pivotal shift towards proactive healthcare,” said Abdel-Mohsen. “This could significantly alter clinical outcomes, allowing for timely interventions and personalised treatment plans. The impact on treatment and management in the HIV community could be revolutionary. Beyond biomarkers, antibodies glycoengineered to mimic biologically younger glycans offer a new therapeutic avenue. This method could enhance immune responses, paving the way for innovative treatments.”
The findings, along with a full list of co-authors and support providers, are detailed in a new paper ‘Immunoglobulin G N-glycan Markers of Accelerated Biological Aging During Chronic HIV Infection, is published in Nature Communications.
More information online:
ilmt.co/PL/MMRl 62594pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148
